Xiaobin Wu Sells $164K of BeOne Medicines Ltd (ONC) — SEC Form 4, Jun 15, 2026

Open-Market Net Sale · SEC Form 4
−$163,512

Equity position changed by +9.8%

Reporting Owner
Xiaobin Wu
COO
TXN 2026-06-11 · FILED 2026-06-15
Equity Position 1.32M sh 1,206,527 → 1,324,526
Equity Change +9.8% shares held after vs before
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

BeOne Medicines Ltd

ONC CIK 0001651308
All BeOne Medicines Ltd insider activity
Filing Date
2026-06-15
Report Date
2026-06-15
Accession No.
0001739452-26-000006
Accepted At
2026-06-15 21:55 UTC
Reporting Owner
Name Relationship
Xiaobin Wu CIK 0001739452
COO
Xiaobin Wu at BeOne Medicines Ltd Full insider history
Bought (12 mo) —
Sold (12 mo) $8,753,697
More from this insider at BeOne Medicines Ltd
2026-08-27 Sell -$106,400 View
2026-06-25 Sell -$356,927 View
2026-06-18 Sell -$361,997 View
2026-06-10 Sell -$399,738 View
2026-03-11 Award — View
All filings by this insider at BeOne Medicines Ltd
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Ordinary SharesF1 2026-06-11 A - Award/Grant 118,625 A $0.00 — 1,308,161 Direct
American Depositary SharesF2F3F4 2026-06-11 S - Sale 626 D $261.20 -$163,512 0 Direct
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Share Option (Right to Buy)F5F5F6 $20.81 2026-06-11 A - Award/Grant 229,775 A $0.00 2036-06-10 229,775 Ordinary Shares Direct
Non-Derivative Holdings
Title Shares Held Ownership
American Depositary SharesF2 12,365 Direct
American Depositary SharesF2 4,000 Indirect By Wife
Footnotes (6)
F1
Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Show more
F2
Each American Depositary Share represents 13 Ordinary Shares. Show more
F3
The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Show more
F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.19 to $261.29, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Show more
F5
The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Show more
F6
These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Show more

Related filings at BeOne Medicines Ltd

Institutional Holders
13F holders · Jun 30, 2026 283 institutional managers reporting a position
Largest by reported value
  1. Baker Bros. Advisors Lp $2.51B
  2. Primecap Management Co/Ca/ $1.43B
  3. Capital International Investors $1.2B
5%+ Holders · 13D/G 2 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BeOne Medicines Ltd
All BeOne Medicines Ltd insider activity
GET /v1/forms/4/0001739452-26-000006 API docs
View Original SEC Filing